🔬 Introduction
In the race to develop effective vaccines against COVID-19, Iranian researchers have designed an innovative mRNA-based vaccine candidate known as COReNAPCIN®. Using a lipid nanoparticle (LNP) delivery system, this vaccine aims to safely express the full-length SARS-CoV-2 spike (S) protein in host cells — triggering strong immune responses. Recent preclinical results show high efficacy and safety in both small and large animal models.
💡 What Makes This Vaccine Unique?
Modified mRNA: Encodes the full spike protein and uses N1-methyl-pseudouridine to improve translation and reduce inflammatory reactions.
LNP Delivery: mRNA is encapsulated in lipid nanoparticles to protect it and ensure targeted delivery into cells.
Efficient Protein Expression: Confirmed in HEK293 cells for up to 72 hours, indicating good mRNA stability and functionality.
🧪 Key Preclinical Findings
In Mice:
Strong IgG and neutralizing antibody responses.
Activation of T cells producing IFN-γ and IL-2.
No weight loss or lung pathology, confirming vaccine safety.
In Rhesus Macaques:
Broad neutralizing antibodies against multiple variants (Wuhan, Delta, Beta).
No detectable viral RNA in lung tissue after virus challenge.
No clinical signs or adverse effects observed.
✅ Conclusion
The COReNAPCIN® mRNA vaccine represents a significant scientific achievement in Iran’s biotechnology sector. Its excellent safety profile and robust immunogenicity in both mice and monkeys mark it as a strong candidate for future clinical trials.
📄 Full Article Reference
Title: Preclinical evaluation of a lipid nanoparticle-encapsulated mRNA-based SARS-CoV-2 vaccine candidate
Journal: Journal of Vaccine X
DOI: https://doi.org/10.1016/j.jvacx.2022.100187
